Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Investigational new drugs

• Publication date

  2003-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1026203418976PMID 14586212
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects

  2001cited by this paper
• Platyphyllin A, A Novel Coumarone from the Leaves of Betula Platyphylla Suk

  2001cited by this paper
• 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.

  2000cited by this paper
• The role of vitamin D3 receptor mRNA in the proliferation of hepatocellular carcinoma.

  2000cited by this paper
• Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2.

  2000cited by this paper
• 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.

  2000cited by this paper
• 1α,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms.

  2000cited by this paper
• 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.

  2000cited by this paper
• The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.

  2000cited by this paper
• Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.

  1999cited by this paper
• A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.

  1999cited by this paper
• Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.

  1999cited by this paper
• Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture.

  1999cited by this paper
• Induction of Androgen Receptor by 1α,25-Dihydroxyvitamin D3 and 9-cis Retinoic Acid in LNCaP Human Prostate Cancer Cells.

  1999cited by this paper
• Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.

  1998cited by this paper
• Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.

  1998cited by this paper
• Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.

  1997cited by this paper
• Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.

  1997cited by this paper
• Evolving concepts in the systemic drug therapy of breast cancer.

  1997cited by this paper
• Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells.

  1997cited by this paper
• Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion.

  1997cited by this paper
• Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.

  1997cited by this paper
• 1,25-dihydroxyvitamin D3 increases the sensitivity of human renal carcinoma cells to tumor necrosis factor alpha but not to interferon alpha or lymphokine-activated killer cells.

  1996cited by this paper
• 1,25-Dihydroxyvitamin D3 increases the sensitivity of human renal carcinoma cells to tumor necrosis factor α but not to interferon α or lymphokine-activated killer cells

  1996cited by this paper
• Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.

  1996cited by this paper
• Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells.

  1996cited by this paper
• 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.

  1995cited by this paper
• Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

  1995cited by this paper
• Role of apoptosis in the growth inhibitory effects of vitamin D in MCF-7 cells.

  1995cited by this paper
• Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.

  1994cited by this paper
• EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells.

  1993cited by this paper
• Two nuclear signalling pathways for vitamin D

  1993cited by this paper
• Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer.

  1993cited by this paper
• Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.

  1993cited by this paper
• The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma.

  1993cited by this paper
• Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.

  1991cited by this paper
• 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice.

  1990cited by this paper
• Enhancement of butyrate-induced differentiation of HT-29 human colon carcinoma cells by 1,25-dihydroxyvitamin D3.

  1989cited by this paper
• The role of the vitamin D endocrine system in health and disease.

  1989cited by this paper
• 1,25-Dihydroxyvitamin D3-induced growth restriction of cultured epithelial cells derived from a murine hepatic tumor.

  1989cited by this paper
• Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization.

  1989cited by this paper
• The vitamin D story: a collaborative effort of basic science and clinical medicine 1

  1988cited by this paper
• Phorbol esters, but not the hormonal form of vitamin D, induce changes in protein kinase C during differentiation of human histiocytic lymphoma cell line (U-937).

  1987cited by this paper
• Inhibitory effect of 1α,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line

  1986cited by this paper
• Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line.

  1986cited by this paper
• Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol).

  1984cited by this paper
• Effect of 1 alpha-hydroxyvitamin D3 on metastasis of rat ascites hepatoma K-231.

  1984cited by this paper
• 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells.

  1984cited by this paper
• Vitamin D metabolites change the phenotype of monoblastic U937 cells.

  1983cited by this paper

• In vitro studies revealed a downregulation of Wnt/β-catenin cascade by active vitamin D and TX 527 analog in a Kaposi's sarcoma cellular model.

  2019cites this paper
• Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.

  2018cites this paper
• The Roles of Vitamin D and Its Analogs in Inflammatory Diseases.

  2016cites this paper
• VITAMIN D AS A PROMISING ANTICANCER AGENT

  2015cites this paper
• The role of vitamin D in cancer prevention.

  2015cites this paper
• Glycosylation of Some Selected Phenols and Vitamins

  2013cites this paper
• Clinical Experience Using Vitamin D and Analogs in the Treatment of Myelodysplasia and Acute Myeloid Leukemia: A Review of the Literature

  2012cites this paper
• What does a modified-Fibonacci dose-escalation actually correspond to?

  2012cites this paper
• A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors

  2011influential citation
• Vitamin D and Prostate Cancer

  2011cites this paper
• Complementary and alternative therapies

  2011cites this paper
• Vitamin D, disease and therapeutic opportunities

  2010cites this paper
• Calcitriol and Vitamin D Analogs

  2010cites this paper
• Silibinin can induce differentiation as well as enhance vitamin D3‐induced differentiation of human AML cells ex vivo and regulates the levels of differentiation‐related transcription factors

  2009cites this paper
• Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia

  2006cites this paper
• Vitamin D Analogs and Their Role in Prostate Cancer

  2006cites this paper
• Promise of vitamin D analogues in the treatment of hyperproliferative conditions

  2006cites this paper
• Cooperation between antioxidants and 1,25‐dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNK/AP‐1/Egr‐1 pathway

  2005cites this paper
• Vitamin D and cancer: an update of in vitro and in vivo data.

  2005cites this paper
• Vitamin D Receptor Gene Polymorphisms and Bone

  2005cites this paper
• Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs.

  2004cites this paper
• Overview of the clinical efficacy of investigational anticancer drugs

  2003cites this paper
• Principles of chemotherapy and drug development

  2002cites this paper